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Background. The utility of repeat EUS in patients with suspicion for pancreatic cancer after non-diagnostic EUS-FNA study is not
well established. Aim. Determine the accuracy of repeat EUS-FNA in patients with suspected pancreatic cancer and prior non-
diagnostic EUS-FNA. Methods. Retrospective cohort study. Results. From 2002 to 2008 in our institution 28 patients underwent
repeat EUS-FNA forsuspected pancreatic cancer.InitialEUS showed a pancreatic massin 24(85.71%),nomassin 3(10.71%)and
possible mass in 1 (3.58%). FNA was performed and was negative for malignancy in all patients. Repeat EUS showed pancreatic
mass in 27 patients (96.42%) and no mass in 1 (3.58%). FNA was performed in all patients and cytology was positive for
malignancyin 6 (21.43%).Out ofthe 28 patients, 17 (60.71%)were eventuallyconﬁrmed to havecancer. Overall repeat EUS-FNA
correctly determined the true ﬁnal status in 17 out of 28 patients providing sensitivity for the diagnosis of cancer of 35% (95% CI
14%–62%), speciﬁcity 100% (95% CI 72%–100%), and overall accuracy of 61%, (95% CI 28%–72%). Conclusion. Repeat EUS-
FNA provides reasonableaccuracy andmaybe worthwhileinpatientswithsuspected pancreaticcancerwhohadhadpriornegative
EUS-FNA.
1.Introduction
Pancreatic cancer caused 35,240 deaths in 2009 making it
the 4th leading cause of cancer-related death in the United
States [1]. The disease typically presents at a late stage given
the lack of early detection methods and late manifestation of
symptoms. The prognosis of pancreatic cancer is grim with
1- and 5-year-survival rates of 24% and 5%, respectively [1].
Surgical resection is the only potentially curative option, but
because of the late disease presentation only 15%–20% of
patients are surgical candidates. Therefore, accurate tissue
diagnosis and staging is imperative prior to considering any
surgical or palliative chemoradiation therapy.
Endoscopicultrasound(EUS)with ﬁneneedleaspiration
(FNA) has been shown to be both safe and accurate in
providing deﬁnitive diagnosis in patients with pancreatic
cancer [2]. Since EUS-FNA is considered the gold standard
for pancreatic cancer staging and tissue acquisition, the
practicing physician is faced with the dilemma of how to
manage patients who have high probability of having cancer
based on clinical presentation but have a non-diagnostic
EUS-guided FNA. A large multicenter study showed that
EUS-FNA of solid pancreatic lesions conﬁrmed malignancy
in 71% of the patients [3]. Therefore, a substantial number
of patients with pancreatic lesions remain with no deﬁnitive
diagnosis despite attempted EUS-FNA,and currentlythere is
no accepted uniﬁed management strategy for such patients.
One approach is to repeat the EUSexam and reattemptFNA,
but there is limited data to support such strategy. The aim of
this study was to determine the accuracy of repeat EUS-FNA
for tissue diagnosis in patients with suspected pancreatic
cancer with an initial non-diagnostic EUS-FNA.2 Gastroenterology Research and Practice
2.Methods
This is a retrospective review of prospectively collected data
in a searchable electronic database. All patients who under-
went more than one EUS-FNA in our institution for eval-
uation of suspected pancreatic cancer with initial non-
diagnostic EUS-FNA were included in this analysis. Patients
were excluded if tissue diagnosis was secured at the ﬁrst
EUS. The deﬁnition of a non-diagnostic EUS-FNA included
cases in which FNAwas attemptedin patients with suspected
pancreatic cancer, but the cytology results were negative
for malignancy for one of the following reasons: adequate
sample material was obtained, but cytology was negative for
malignancy, less than the predetermined minimum of four
FNA passes were made for any reason, and successful four
FNApasses were carried out,butinadequatesample material
was obtained.
All patients provided informed consent. EUS was done
using the curvilinear echoendoscope (Olympus UC-30P,
or UCT 140; Olympus America Inc, Center Valley, PA)
as previously described [4]. Brieﬂy, all cases were done
using endoscopist-guided sedation using combination of
meperidine or fentanyl with midazolam with the goal to
achieve moderate sedation. With the patient in left lateral
decubitusposition, the echoendoscope was inserted, and the
pancreas was indentiﬁed. Features of chronic pancreatitis
were systematically documented as previously deﬁned [5].
Patients with four or more features were considered to have
chronic pancreatitis. Color Doppler was used to exclude
intervening vascular structures and to choose a vessel-free
needle track. All FNAs were performed utilizing Echo-tip
22 French gauge EUS needle (Cook Endoscopy, Winston-
Salem, NC). Suction via the needle was applied in all
cases. The FNA samples were evaluated immediately for
adequacy by a cytopathology technician. The goal was to
obtain at least four passes from the lesion unless cytological
evaluation performed on site conﬁrmed the presence of
malignant cells. We utilized the ﬁnal cytology reports for
ouranalysis. Cytologywascategorizedas(1)benign/reactive,
(2) atypical, (3) suspicious, or (4) malignant. The ﬁnal
diagnosis of pancreatic cancer was deﬁned based on one of
the following criteria: (1) positive cytology at the second
EUS, (2) positive cytology or histology obtained by alter-
native means (e.g., surgical biopsy), (3) clinical progression
judged by evolving local invasion or metastatic disease
on followup computed tomography (CT) or magnetic
resonance imaging (MRI), or (4) death from the disease
within12monthsofinitialpresentation.Complicationswere
deﬁned and graded based on accepted consensus criteria [6].
Complications were assessed during the procedure and in
the postprocedure recovery area and then by telephone
call the day after the procedure. All detected complica-
tions were entered in a dedicated searchable electronic
database.
2.1. Ethics. The study was approved by the institutional
review board (IRB) at the University of Florida, and all
patients signed informed consent.
2.2. Statistics. Continuous variables were reported as means
and standard deviation, while categorical variables were
reported as proportions. Statistical analysis was performed
by using SAS version 9.1 (SAS institute, Cary, NC). The
sensitivity, speciﬁcity, positive predictive value, and negative
predictive value of EUS 1 and EUS 2 were calculated. 95%
conﬁdenceintervalsofthosestatisticswerealsocalculatedfor
comparison [7].
3.Results
From January 2002 to November2008, total of 3895 patients
underwent EUS in our institution. Of these, 30 (0.77%) had
repeat EUS-FNA for the evaluation of possible pancreatic
cancer. Two patients were excluded since tissue diagnosis of
malignancy was established with the ﬁrst EUS-FNA, but a
repeat study was requested to obtain additional tissue for
special staining. The remaining 28 patients (12 male, 16
female), mean age 62 years (range 34–82), were included in
the analysis, and the results are reported.
The most common presenting symptoms were abdom-
inal pain (78.57%), weight loss (64.29%), and nau-
sea/vomiting (39.29%) (Table 1). The indication for the
initialEUSwas abnormalCTorMRIﬁndings in27(96.43%)
patients and endoscopic retrograde cholangiopancreatogra-
phy (ERCP) abnormalities in 1 (3.57%). Preprocedure CT
or MRI showed deﬁnitive or possible pancreatic mass in 26
patients (88.89% and 7.41%, resp.) and no desecrate mass in
1 (3.70%), whose indication for the EUS was common bile
duct stricture on ERCP.
Initial EUS evaluation showed pancreatic mass in 24
(85.71%), no mass in 3 (10.71%) patients, and possible mass
in 1 (3.58%). FNA was done in all 28 (100%) patients. Initial
exam was limited, and less than four FNA passes were made
in 5 patients (17.86%) due to diﬃculty in positioning the
echoendoscope or sedating in 3 patients (10.74%), presence
of ascites and vascular collaterals in 1 (3.58%), and food
obstructing view in 1 (3.58%). The mean number of FNA
passes on initial EUS was 4.82 (1–7, range). Cytologic
evaluation of the FNA specimen was “atypical” in 1 (3.58%),
“suspicious” in 4 (14.28%), and “benign/reactive” in 23
(82.14%). No complications were related to the ﬁrst EUS.
Repeat EUS was performed in all patients after mean
of 33 days (range 2–140 days) from the initial EUS exam.
At the second EUS-FNA, a pancreatic mass was seen in
27 patients (96.42%) and no mass in 1 (3.58%). The
patient in whom no mass was seen had a distal bile duct
stricture and biliary stent. FNA was obtained from the area
immediately surroundingthestent.Cytologywaspositivefor
malignancy on repeat EUS-FNA in 6 (21.43%) patients. The
second EUS established the tissue diagnosis of malignancy
in 1 (3.58%) patient with prior atypical/suspicious ﬁndings
at the ﬁrst EUS and in 5 (17.85%) of the patients with
benign/reactive initial cytology. Based on the location of the
lesion, malignancy was diagnosed at the second EUS-FNA
in 3 (50%) of the lesions in the head/uncinate process and
in 3 (50%) of the lesions in the neck, body, and tail. The
mean number of FNA passes on the repeat EUS examinationGastroenterology Research and Practice 3
Table 1: Patient presenting symptoms.
Initial presentation of patient
Asymptomatic 39.29% (n = 11)
Jaundice 35.71% (n = 10)
Pruritis 3.58% (n = 1)
Weight loss 64.29% (n = 18)
Abdominal pain 78.57% (n = 22)
Nausea/vomiting 39.29% (n = 11)
Early satiety 25.00% (n = 7)
Lethargy 17.86% (n = 5)
Unknown 10.71% (n = 3)
was 4.82 (range 2–8). Overall repeat EUS-FNA established
deﬁnitive tissue diagnosis of malignancy in 6 out of 28
patients (21.43%). There were not complications related to
the second EUS.
Out of the 28 patients in this cohort, 17 (60.71%) were
eventually conﬁrmed to have cancer. Tissue sampling con-
ﬁrmed malignancy in 11/17 (64.71%), and clinical criterion
(progressing metastatic disease/local invasion on imaging,
or death within 1 year upon presentation) established
malignancyin6/17(35.29%).Ofthe11patientsinwhomthe
diagnosis of malignancy was established by tissue pathology,
adenocarcinoma was present in 8/11(72.73%), and there
was one case of neuroendocrine tumor (9.09%) lymphoma
(9.09%) and spindle cell neoplasm (9.09%). Repeat EUS-
FNAwasabletoprovidetissueconﬁrmationin6(35.29%)of
the patients eventually found to have pancreatic malignancy
(n = 17).
Accordingto our predetermined criteria, 11/28 (39.29%)
of the patients were considered to have no malignancy. One
(9.09%) was diagnosed with autoimmune pancreatitis, 4
(36.36%) had chronic pancreatitis-associated inﬂammatory
head masses which eventually resolved on followup imaging,
2 (18.18%) had chronic calciﬁc pancreatitis, and in 4
(36.36%) patients no deﬁnitive diagnosis was established. Of
these 4 patients without established deﬁnitive diagnosis but
classiﬁedas having benigndisease, twohada pancreaticmass
by both CT and EUS; however, both died from unrelated
causes, respectively, two and a half and three years after
presentation. The third patient had a suspected pancreatic
mass on CT scan, but deﬁnitive mass was not seen on EUS.
EUS-FNA was repeated total of three times, and all cytology
specimens were benign. The patient is still alive and stable
over2.5 years. Lastly, the 4th patientwas lost tofollowup and
was considered as having benign disease in this intention to
treat analysis.
Repeat EUS-FNA correctly determined the true ﬁnal
status in 17 out of 28 patients providing a sensitivity for the
diagnosis of cancer of 35% (95% CI 14%–62%), speciﬁcity
of 100% (95% CI 72%–100%), and overall accuracy for
determination of the true ﬁnal status of the patients of 61%
(95% CI 28%–72%).
4.Discussion
The main ﬁnding of our study is that, in patients with
suspected pancreatic cancer and negative EUS-FNA, repeat
EUS-FNA had a moderate clinical yield. Repeat EUS-FNA
was accurate in predicting the ﬁnal malignant/benign status
in 61% of the patients and provided positive tissue diagnosis
in 35% of the patients eventually found to have pancreatic
malignancy.
At present, there is no universally accepted strategy on
how to manage patients presenting with clinical history
and imaging ﬁndings suggestive of pancreatic malignancy
but who have negative cytology on EUS-FNA. The cur-
rently available options consist of clinical observation with
serial imaging, CT-guided biopsy, surgical exploration with
“blind” pancreatic resection, chemoradiation therapy with-
out deﬁnitive tissue diagnosis, and repeat EUS-FNA.Clinical
observation is rarely a feasible option due to the high anxiety
associated with the potential diagnosis of pancreatic cancer,
and CT-guided biopsy has fallen out of favor mostly due to
the increased risk of intraperitoneal spread of the cancer via
the needle track and worse outcome even in patients that
are not surgical candidates [8]. Surgical exploration done
purely for tissue diagnosis is rarely carried out in patients
who are not candidates for pancreatic resection due to the
high degree of invasiveness but can be considered in patients
who appearresectablebasedonimagingand areotherwise ﬁt
for surgery. The appeal of “blind” pancreatic resection and
chemoradiation therapy without deﬁnitive tissue diagnosis
has signiﬁcantly diminished considering the medicolegal
climate in the US. Finally, in patients with clinical suspicion
for pancreatic malignancy and negative EUS-FNA, one
can consider repeating the EUS exam and reattempting
FNA. This repeat EUS-FNA strategy is appealing due to
the minimally invasive nature of EUS and its excellent
safety record, but the data in support of such approach
are limited. In patients evaluated with EUS for various
indications, DeWitt et al. reported that repeat examination
had a clinical impact in 63% of patients [9]. To date only
study has speciﬁcally evaluated the value of repeat EUS-FNA
in patients presenting with suspicion for pancreatic cancer
[10]. In these series of 24 patients, the reported accuracy
of the repeat EUS-FNA was found to be 84% [10]. The
current study expands on these previous ﬁndings. Despite
our somewhat lower accuracy of 61%, our ﬁndings reaﬃrm
that repeat EUS-FNA is a reasonable management strategy.
Our study is not without limitations. All cases were done
in a tertiary referral center by highly experienced endosono-
graphers raising concernsaboutthe applicabilityof ourﬁnd-
ings in various practice settings. Furthermore, our patient
population is relatively small, and therefore the study did
not have enough power to evaluate for any predictors for
success/failure for the repeat EUS-FNA. In addition, in our
study, we aimed to obtain minimum of 4 FNA passes per
patient. Unfortunately, there is no uniform consensus on the
optimal number of needle passes needed to obtain correct
diagnosis. Earlier ﬁndings demonstrated that an average
of 3.44 passes provided adequate cytological sampling, but
more recent higher quality prospective study revealed that4 Gastroenterology Research and Practice
7 passes are needed to achieve FNA sensitivity of 83%
[11, 12]. Finally, we did not have data on the serum levels
of immunoglobulin G subclass 4 (IgG4) in most patients
since the importance of autoimmune pancreatitis as a cause
of pancreatic mass lesions has been just recently fully
appreciated [13].
In conclusion, in patients with suspicion for pancreatic
cancer and negative EUS-FNA, a repeat EUS-FNA can pro-
vide tissue diagnosis in approximately one-third of patients
eventually found to have malignancy. Although repeat EUS-
FNA provides a relatively low sensitivity and accuracy, it
still appears an attractive option given its minimally invasive
nature, excellent safety record, suboptimal alternatives for
tissue sampling, and the ramiﬁcations of a lack of deﬁnitive
tissue diagnosis.
Abbreviations
EUS: Endoscopic ultrasound
FNA: Fine needle aspiration
ERCP: Endoscopic retrograde cholangiopancreatography
CT: Computed tomography
MRI: Magnetic resonance imaging.
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